Table 2.

The difference of AEs between intervention group and control group.

Adverse events	Subgroup	n	Subgroup OR (95% CI)	Subgroup P value	Pooled OR (95% CI)	Pooled P value
Hypertension	Sorafenib	3	2.35 (0.71, 7.82)	0.160	3.47 (2.10, 5.74)	<0.001
	Sunitinib	3	4.69 (3.21, 6.86)	<0.001
	Pazopanib	1	4.65 (3.17, 6.83)	<0.001
Rash	Sorafenib	3	28.51 (11.11, 73.15)	<0.001	15.38 (8.00, 29.57)	<0.001
	Sunitinib	3	4.62 (1.66, 12.86)	0.003
	Pazopanib	1	2.95 (0.12, 72.63)	0.510
Diarrhea	Sorafenib	3	14.84 (6.02, 36.59)	<0.001	14.56 (8.46, 25.05)	<0.001
	Sunitinib	3	18.03 (7.30, 44.52)	<0.001
	Pazopanib	1	9.93 (3.52, 28.01)	<0.001
Hand-foot syndrome	Sorafenib	3	41.82 (20.81, 84.02)	<0.001	26.29 (16.72, 41.34)	<0.001
	Sunitinib	3	16.33 (8.80, 30.29)	<0.001
	Pazopanib	1	23.04 (1.35, 391.95)	0.030
Nausea	Sorafenib	3	3.01 (0.85, 10.68)	0.090	8.08 (3.37, 19.35)	<0.001
	Sunitinib	3	17.41 (4.18, 72.53)	<0.001
	Pazopanib	1	4.93 (0.24, 102.91)	0.300
Fatigue	Sorafenib	3	2.24 (1.39, 3.62)	0.001	4.06 (2.98, 5.54)	<0.001
	Sunitinib	3	5.94 (3.90, 9.05)	<0.001
	Pazopanib	NR	—	—
Vomiting	Sorafenib	2	2.68 (0.71, 10.12)	0.150	4.50 (2.04, 9.93)	<0.001
	Sunitinib	3	7.10 (2.31, 21.81)	<0.001
	Pazopanib	1	0.98 (0.06, 15.74)	0.990
Mucositis	Sorafenib	2	11.16 (2.09, 59.45)	0.005	16.07 (5.85, 44.12)	<0.001
	Sunitinib	3	22.71 (5.50, 93.77)	<0.001
	Pazopanib	1	4.93 (0.24, 102.91)	0.300
Neutropenia	Sorafenib	2	2.44 (1.27, 4.70)	0.008	2.99 (1.92, 4.67)	<0.001
	Sunitinib	3	3.52 (1.91, 6.46)	<0.001
	Pazopanib	NR	—	—
Headache	Sorafenib	1	3.02 (1.79, 5.10)	<0.001	2.72 (1.89, 3.93)	<0.001
	Sunitinib	2	2.48 (1.46, 4.20)	<0.001
	Pazopanib	1	1.97 (0.18, 21.77)	0.580
Decreased appetite	Sorafenib	1	11.05 (0.61, 200.31)	0.100	11.56 (2.73, 48.9)	<0.001
	Sunitinib	2	15.18 (2.01, 114.88)	0.008
	Pazopanib	1	4.93 (0.24, 102.91)	0.300

OR: odds ratio; CI: confidence interval; NR: not reported.